PepsDoes Semax improve memory and focus in healthy people?
The claim
“Semax improves memory and focus in healthy people.”
Verdict: Unproven
Semax is used as a medicine in Russia, mainly in stroke care, and its developers report that it improves memory and attention. But we found no published, placebo-controlled trial in healthy people that measured memory or focus. The healthy-volunteer studies we found looked at brain scans, not at test performance.
Not on the published evidence. Semax is a synthetic seven-amino-acid peptide based on a piece of the hormone ACTH, developed in Russia. Russian clinical studies, mostly small and published in Russian, report benefits after stroke and in some other brain and nerve conditions, and rat studies link it to a brain growth factor called BDNF. The claim of sharper memory and focus in healthy people rests on statements by the drug's developers rather than on published trials.
What Semax is and where it is used
Semax is a seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro). It is an analog of a fragment of adrenocorticotropic hormone known as ACTH 4-10, a piece of the hormone that researchers had linked to effects on learning and attention.
In a 1997 review, its Russian developers described Semax as one of the few regulatory peptides to go all the way from basic research to practical medical use, and said it was being used to treat patients with a range of nervous system diseases. Russian authors have called it a new Russian drug and say it is used in clinical practice for patients with severe disorders of blood flow to the brain.
Sources: PubMed 16996037 · PubMed 9173745 · PubMed 10741256 · PubMed 20617398
The stroke and neurology studies
Most clinical research on Semax comes from Russian stroke units. In a 1997 study, 30 patients with acute ischemic stroke received Semax on top of standard care and were compared with 80 patients of similar severity on standard care alone. The authors reported faster recovery of neurological function, especially movement. A 1999 analysis of blood markers in stroke patients reported a shift toward anti-inflammatory signals. In a 2018 study of 110 patients in stroke rehabilitation, those who also received Semax had higher blood levels of the growth factor BDNF and better recovery in daily activities.
Other Russian studies reported fewer strokes and better symptoms in 187 patients with chronic poor blood flow to the brain. In an open-label study of 27 patients with motor neuron disease, Semax did not change nerve test results or the course of the disease, although quality-of-life scores improved. These are studies of people with brain or nerve disease, not healthy people.
Sources: PubMed 11517472 · PubMed 10358912 · PubMed 29798983 · PubMed 15792140 · PubMed 18379501
How strong is that evidence?
The clinical evidence is thin by international standards. The studies are small, most are published only in Russian, and their abstracts do not describe placebo-controlled, double-blind designs. Several were written by the peptide's developers. Comparison groups were often patients on standard treatment rather than patients given a placebo, which makes it hard to separate the drug's effect from differences in care or expectations.
Outside Russia, this work has had little visibility. In 2020, a Belgian government medicines laboratory that identified Semax in seized products described it as a research peptide that, to the authors' knowledge, had not completed any clinical trials. That is not strictly accurate given the Russian studies, but it shows how little of the evidence has reached international journals or regulators.
Sources: PubMed 11517472 · PubMed 29798983 · PubMed 31667971
The animal studies behind the memory claim
Much of the memory story comes from rats. In a 2006 study, a single intranasal application of Semax raised levels of BDNF, a protein that supports the growth and plasticity of brain cells, by up to 1.4-fold in the rat hippocampus, a region central to memory. Treated rats also performed more learned avoidance responses. A companion study found specific binding sites for Semax and a rapid BDNF increase in the rat basal forebrain.
These findings suggest a plausible mechanism, and the authors proposed that BDNF might explain Semax's effects on learning. But rat brain chemistry and rat avoidance learning are a long way from memory or concentration in healthy adults, and these studies were not designed to show either.
Sources: PubMed 16996037 · PubMed 16635254
What has been tested in healthy people
The developers' 1997 review states that Semax significantly improves memory and attention in healthy men working under extreme conditions. However, the review abstract gives no details of how this was tested, and we could not find the underlying study published with an abstract in PubMed. Two more recent Russian studies did give Semax to healthy volunteers, but they measured brain activity at rest with functional MRI. One, in 24 adults, found a change in a brain network called the default mode network after Semax compared with placebo. The other, in 52 participants, compared Semax, a related peptide called Selank and placebo and found changes in connections between brain regions. Neither abstract reports memory or attention test results.
A related molecule gives a reason for caution. In a 2000 German placebo-controlled study of 60 healthy people, the parent fragment ACTH 4-10, which Semax was built from, did not improve working memory. It increased errors on a vigilance task and briefly worsened recall of neutral words. Semax is a different molecule, so this does not prove it would behave the same way, but it shows that the parent fragment did not sharpen focus when it was properly tested.
Sources: PubMed 9173745 · PubMed 30225715 · PubMed 32342318 · PubMed 10917406
Regulatory status and product concerns
The FDA lists Semax among bulk drug substances that may present significant safety risks in compounding. It says compounded Semax may carry a risk of immune reactions because of aggregation and peptide-related impurities, that it has little or no safety information for the proposed routes of use, and that it therefore cannot tell whether the drug would cause harm.
The Belgian laboratory that found Semax in seized products noted that such peptides are readily available online as powders and nasal sprays, outside any quality control. Combined with the lack of published trials in healthy people, that means anyone using Semax for memory or focus is relying on untested claims about an unregulated product.
Sources: fda.gov · PubMed 31667971
Profiles
References
- Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res · 2006 · PMID 16996037
- [A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)]. Zh Vyssh Nerv Deiat Im I P Pavlova · 1997 · PMID 9173745
- [Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]. Vestn Oftalmol · 2000 · PMID 10741256
- The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. J Mol Neurosci · 2011 · PMID 20617398
- [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova · 1997 · PMID 11517472
- [Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova · 1999 · PMID 10358912
- [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova · 2018 · PMID 29798983
- [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]. Zh Nevrol Psikhiatr Im S S Korsakova · 2005 · PMID 15792140
- [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]. Zh Nevrol Psikhiatr Im S S Korsakova · 2007 · PMID 18379501
- The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Test Anal · 2020 · PMID 31667971
- Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem · 2006 · PMID 16635254
- Effects of Semax on the Default Mode Network of the Brain. Bull Exp Biol Med · 2018 · PMID 30225715
- Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci · 2020 · PMID 32342318
- Event-related brain potentials and working memory function in healthy humans after single-dose and prolonged intranasal administration of adrenocorticotropin 4-10 and desacetyl-alpha-melanocyte stimulating hormone. J Clin Psychopharmacol · 2000 · PMID 10917406
Other sources
These are original summaries of published research, written with AI assistance and checked against the cited sources. They are not medical advice and have not been reviewed by a clinician. Every PubMed reference was checked against PubMed's record for title, year and journal. All claim checks · Editorial standards